Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The influenza A vaccine + influenza B vaccine refers to combination influenza vaccines that include antigens from both influenza A virus subtypes and influenza B viruses. These vaccines are inactivated (killed virus) or recombinant protein vaccines engineered to induce immunity and prevent infection from circulating seasonal influenza A and B viruses. They work by stimulating the production of virus-neutralizing antibodies, targeting the viral hemagglutinin (HA) proteins of both influenza A and B strains. Commonly, they are formulated as trivalent (containing two A strains and one B strain) or quadrivalent (containing two A and two B strains) vaccines. Their primary use is the prevention of seasonal influenza in children and adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on influenza A vaccine + influenza B vaccine.